Hansoh Pharmaceutical (Aumolertinib License) Overview

  • Status
  • Acquired/​Merged

  • Latest Deal Type
  • Asset Purch.

  • Financing Rounds
  • 1

Hansoh Pharmaceutical (Aumolertinib License) General Information

Description

Aumolertinib license assets based in China. The license consists for research, development and commercialization of aumolertinib.

Contact Information

Ownership Status
Acquired/Merged
Financing Status
Corporate Backed or Acquired
Corporate Office
  • China
Primary Industry
Buildings and Property
Other Industries
Biotechnology
Acquirer
Corporate Office
  • China

Want detailed data on 11M+ companies?

What you see here scratches the surface

Request a free trial

Want to dig into this profile?

We’ll help you find what you need

Learn more

Hansoh Pharmaceutical (Aumolertinib License) Valuation & Funding

Deal Type Date Amount Valuation/
EBITDA
Post-Val Status Debt

This information is available in the PitchBook Platform. To explore Hansoh Pharmaceutical (Aumolertinib License)‘s full profile, request access.

Request a free trial

Hansoh Pharmaceutical (Aumolertinib License) Former Investors

Investor Name Investor Type Holding Investor Since Participating Rounds Contact Info

This information is available in the PitchBook Platform. To explore Hansoh Pharmaceutical (Aumolertinib License)‘s full profile, request access.

Request a free trial

Hansoh Pharmaceutical (Aumolertinib License) FAQs

  • Where is Hansoh Pharmaceutical (Aumolertinib License) headquartered?

    Hansoh Pharmaceutical (Aumolertinib License) is headquartered in China.

  • What industry is Hansoh Pharmaceutical (Aumolertinib License) in?

    Hansoh Pharmaceutical (Aumolertinib License)’s primary industry is Buildings and Property.

  • Is Hansoh Pharmaceutical (Aumolertinib License) a private or public company?

    Hansoh Pharmaceutical (Aumolertinib License) is a Private company.

  • What is Hansoh Pharmaceutical (Aumolertinib License)’s current revenue?

    The current revenue for Hansoh Pharmaceutical (Aumolertinib License) is .

  • Who are Hansoh Pharmaceutical (Aumolertinib License)’s investors?

    Hansoh Pharma has invested in Hansoh Pharmaceutical (Aumolertinib License).

  • When was Hansoh Pharmaceutical (Aumolertinib License) acquired?

    Hansoh Pharmaceutical (Aumolertinib License) was acquired on 22-Jul-2020.

  • Who acquired Hansoh Pharmaceutical (Aumolertinib License)?

    Hansoh Pharmaceutical (Aumolertinib License) was acquired by EQRx.

Data Transparency

  • Meet our data hygiene team

    Discover how our experts ensure you’re getting the most accurate financial data in the industry.

    Read more
  • How PitchBook sources data

    Our data operations team has logged over 3.5 million hours researching, organizing, and integrating the information you need most.

    Discover our process